$738 Million is the total value of Meditor Group Ltd's 40 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | New | MERCK & CO.INC. | $86,704,000 | – | 1,866,600 | +100.0% | 11.74% | – |
| ONXX | New | ONYX PHARMACEUTICALS INC | $83,530,000 | – | 962,103 | +100.0% | 11.31% | – |
| GOOGL | New | GOOGLE INC-CL Acl a | $76,856,000 | – | 87,300 | +100.0% | 10.41% | – |
| EXEL | New | EXELIXIS INC | $54,480,000 | – | 12,000,000 | +100.0% | 7.38% | – |
| VVUS | New | VIVUS INC | $52,928,000 | – | 4,207,296 | +100.0% | 7.17% | – |
| ALKS | New | ALKERMES PLC | $48,756,000 | – | 1,700,000 | +100.0% | 6.60% | – |
| HPQ | New | HEWLETT-PACKARD CO | $41,575,000 | – | 1,676,423 | +100.0% | 5.63% | – |
| NYX | New | NYSE EURONEXT | $32,129,000 | – | 776,070 | +100.0% | 4.35% | – |
| BBRY | New | RESEARCH IN MOTION | $23,117,000 | – | 2,210,000 | +100.0% | 3.13% | – |
| SFD | New | SMITHFIELD FOODS INC | $21,320,000 | – | 651,000 | +100.0% | 2.89% | – |
| 6107SC | New | URS CORP | $16,999,000 | – | 360,000 | +100.0% | 2.30% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $16,748,000 | – | 1,450,000 | +100.0% | 2.27% | – |
| AAPL | New | APPLE INC | $16,258,000 | – | 41,000 | +100.0% | 2.20% | – |
| LIFE | New | LIFE TECHNOLOGIES CORP | $16,058,000 | – | 217,000 | +100.0% | 2.18% | – |
| ISIS | New | ISIS PHARMACEUTICALS INC | $13,972,000 | – | 520,000 | +100.0% | 1.89% | – |
| BKS | New | BARNES & NOBLE INC | $13,965,000 | – | 875,000 | +100.0% | 1.89% | – |
| ITMN | New | INTERMUNE INC | $13,228,000 | – | 1,375,000 | +100.0% | 1.79% | – |
| LBTYK | New | LIBERTY GLOBAL PLC-SERIES Ccl c | $11,491,000 | – | 169,254 | +100.0% | 1.56% | – |
| WCRX | New | WARNER CHILCOTT PLC-CL A | $11,268,000 | – | 566,000 | +100.0% | 1.53% | – |
| OREX | New | OREXIGEN THERAPEUTICS INC | $11,106,000 | – | 1,900,000 | +100.0% | 1.50% | – |
| OPTR | New | OPTIMER PHARMACEUTICALS INC | $6,873,000 | – | 475,000 | +100.0% | 0.93% | – |
| UHS | New | UNIVERSAL HEALTH SERVICES-Bcl b | $6,696,000 | – | 100,000 | +100.0% | 0.91% | – |
| SHPG | New | SHIRE PLC-ADRadr | $6,658,000 | – | 70,000 | +100.0% | 0.90% | – |
| BMC | New | BMC SOFTWARE INC | $6,634,000 | – | 147,000 | +100.0% | 0.90% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $4,484,000 | – | 144,647 | +100.0% | 0.61% | – |
| ECYT | New | ENDOCYTE INC | $4,399,000 | – | 335,000 | +100.0% | 0.60% | – |
| NDAQ | New | NASDAQ OMX GROUP/THE | $4,092,000 | – | 124,793 | +100.0% | 0.55% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $4,048,000 | – | 250,000 | +100.0% | 0.55% | – |
| APC | New | ANADARKO PETROLEUM CORP | $3,609,000 | – | 42,000 | +100.0% | 0.49% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $3,613,000 | – | 270,000 | +100.0% | 0.49% | – |
| MU | New | MICRON TECHNOLOGY INC | $3,325,000 | – | 232,000 | +100.0% | 0.45% | – |
| BAC | New | BANK OF AMERICA CORP | $3,138,000 | – | 244,000 | +100.0% | 0.42% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $3,006,000 | – | 900,000 | +100.0% | 0.41% | – |
| SQNM | New | SEQUENOM INC | $2,947,000 | – | 700,000 | +100.0% | 0.40% | – |
| VALE | New | VALE SA-SP ADRadr | $2,885,000 | – | 219,400 | +100.0% | 0.39% | – |
| PACD | New | PACIFIC DRILLING SA | $2,690,000 | – | 275,000 | +100.0% | 0.36% | – |
| DAL | New | DELTA AIR LINES INC | $2,320,000 | – | 124,000 | +100.0% | 0.31% | – |
| HAL | New | HALLIBURTON CO | $2,295,000 | – | 55,000 | +100.0% | 0.31% | – |
| CCL | New | CARNIVAL CORPctf | $1,564,000 | – | 45,600 | +100.0% | 0.21% | – |
| MSFT | New | MICROSOFT CORP | $691,000 | – | 20,000 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-07-29
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EXELIXIS INC | 43 | Q4 2023 | 88.9% |
| ALKERMES PLC | 31 | Q4 2020 | 62.6% |
| ISHARES MSCI INDIA ETF | 31 | Q4 2023 | 5.5% |
| WISDOMTREE INDIA EARNINGS FUND | 31 | Q4 2023 | 5.5% |
| ESPERION THERAPEUTICS INC | 27 | Q4 2023 | 34.4% |
| VIVUS INC | 15 | Q4 2016 | 21.3% |
| CELLDEX THERAPEUTICS | 14 | Q2 2020 | 2.7% |
| PROSHARES ULTRAPRO SHORT S&P500 | 4 | Q4 2017 | 3.8% |
| PROSHARES ULTRASHORT S&P500 | 4 | Q4 2017 | 3.0% |
| PROSHARES ULTRASHORT S&P 500 ETF | 3 | Q3 2019 | 0.8% |
View Meditor Group Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXELIXIS, INC. | April 09, 2019 | 15,001,073 | 5.0% |
| VIVUS INC | December 19, 2012 | 5,002,896 | 5.0% |
| VIVUS INC | March 21, 2012 | 6,177,500 | 6.3% |
| VION PHARMACEUTICALS INC | February 15, 2008 | 5,736,200 | 7.6% |
| CYPRESS BIOSCIENCE INC | September 26, 2007 | 1,864,645 | 5.0% |
| ONYX PHARMACEUTICALS INC | September 12, 2007 | 2,627,800 | 4.8% |
| ACUSPHERE INC | July 26, 2007 | 1,839,421 | 4.0% |
| NOVACEA INC | June 11, 2007 | 800,000 | 3.4% |
| ATHEROGENICS INC | May 02, 2007 | 1,361,800 | 3.5% |
View Meditor Group Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-11 |
| 13F-HR | 2024-01-04 |
| SC 13G/A | 2024-01-03 |
| 13F-HR | 2023-10-31 |
| 13F-HR | 2023-07-25 |
| 13F-HR | 2023-04-10 |
| 13F-HR | 2023-01-05 |
| SC 13G/A | 2023-01-04 |
| 13F-HR | 2022-11-07 |
| 13F-HR | 2022-07-18 |
View Meditor Group Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.